Wu Zhenzhen, Wang Yueyuan, Li Juan, Wang Huiling, Tuo Xunyuan, Zheng Jing
Department of Gynecology, Gansu Provincial Maternity and Child-Care Hospital, Lanzhou, China.
Department of Pathology, Gansu Provincial Maternity and Child-Care Hospital, Lanzhou, China.
Front Genet. 2022 May 19;13:864578. doi: 10.3389/fgene.2022.864578. eCollection 2022.
Microchromosome maintenance protein 10 (MCM10) is required for DNA replication in all eukaryotes, and it plays a key role in the development of many types of malignancies. However, we currently still do not know the relationship between MCM10 and ovarian cancer (OV) prognosis and immune checkpoints. : The Gene Expression Profiling Interactive Analysis and Tumor Immunology Estimation Resource (TIMER) databases were used to investigate MCM10 expression in Fan cancer. The Kaplan-Meier Plotter and PrognoScan were used to assess the relationship between MCM10 and OV prognosis. The LinkedOmics database was used to analyze the MCM10 co-expression network and explore GO term annotation and the KEGG pathway. The relationship between MCM10 expression and immune infiltration in OV was investigated using the Tumor Immunology Estimation Resource database. cBioPortal database was used to explore the relationship between MCM10 expression and 25 immune checkpoints. Finally, quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect MCM10 expression. The prognosis was also analyzed by distinguishing between high and low expression groups based on median expression values. : The results of the three data sets (220,651_s_at, 222,962_s_at and 223,570_at) in KM Plotter all indicated that the overall survivalof the high MCM10 expression group was lower than that of the low expression group OV, and the results of GSE9891 also reached the same conclusion. The expression level of MCM10 was negatively correlated with B cells and CD8+T cells, and positively correlated with CD4+T Cells and Macrophages. GO term annotation and KEGG pathway analysis showed that the co-expressed genes of MCM10 were mainly enriched in cell cycle and DNA replication. The alterations in MCM10 coexisted statistically with the immune checkpoints CTLA4, TNFSF4, TNFSF18, CD80, ICOSLG, LILRB1 and CD200. PCR results displayed that MCM10 was highly expressed in OV tissues, and the increased expression of MCM10 was significantly associated with poor overall survival. : These results demonstrated that high expression of MCM10 was associated with poor prognosis in OV and correlated with immune checkpoints.
微小染色体维持蛋白10(MCM10)在所有真核生物的DNA复制中都是必需的,并且在多种恶性肿瘤的发生发展中起关键作用。然而,我们目前仍不清楚MCM10与卵巢癌(OV)预后及免疫检查点之间的关系。:利用基因表达谱交互式分析数据库和肿瘤免疫评估资源(TIMER)数据库研究MCM10在卵巢癌中的表达情况。使用Kaplan-Meier Plotter和PrognoScan评估MCM10与OV预后之间的关系。利用LinkedOmics数据库分析MCM10共表达网络,并探索基因本体(GO)术语注释和京都基因与基因组百科全书(KEGG)通路。使用肿瘤免疫评估资源数据库研究MCM10表达与OV中免疫浸润的关系。利用cBioPortal数据库探索MCM10表达与25种免疫检查点之间的关系。最后,进行定量实时聚合酶链反应(qRT-PCR)检测MCM10的表达。还根据中位表达值区分高表达组和低表达组来分析预后情况。:KM Plotter中三个数据集(220,651_s_at、222,962_s_at和223,570_at)的结果均表明,MCM10高表达组的OV总生存期低于低表达组,GSE9891的结果也得出了相同结论。MCM10的表达水平与B细胞和CD8 + T细胞呈负相关,与CD4 + T细胞和巨噬细胞呈正相关。GO术语注释和KEGG通路分析表明,MCM10的共表达基因主要富集在细胞周期和DNA复制中。MCM10的改变与免疫检查点CTLA4、TNFSF4、TNFSF18、CD80、ICOSLG、LILRB1和CD200在统计学上共存。PCR结果显示,MCM10在OV组织中高表达,MCM10表达增加与总生存期差显著相关。:这些结果表明,MCM10高表达与OV预后不良相关,并与免疫检查点相关。